byiShook Opinion
Aug 15, 2024 - 09:35
Diabetes treatments from Merck, Novo Nordisk and AstraZeneca will face the steepest cuts under the IRA, a list showed Thursday. The post Medicare Slashes Merck, Novo, AstraZeneca Drug Prices Up To 79% In IRA Negotiations appeared first on Investor's Business Daily.
Diabetes treatments from Merck, Novo Nordisk and AstraZeneca will face the steepest cuts under the IRA, a list showed Thursday.
The post Medicare Slashes Merck, Novo, AstraZeneca Drug Prices Up To 79% In IRA Negotiations appeared first on Investor's Business Daily.